Researchers investigated the potential association between cutaneous lymphoma and anti-TNFα therapy in a recent study.

FDA Alerts

FDA Alerts
Tuesday, January 2, 2018
The FDA has approved a generic topical solution for the treatment of chronic, moderately severe psoriasis of the scalp.
FDA Alerts
Monday, December 4, 2017
The FDA has expanded the approval of a psoriasis drug to now treat adults with psoriatic arthritis.
FDA Alerts
Monday, October 23, 2017
The FDA has approved extended use of a rheumatoid arthritis drug for the treatment of adult patients with active psoriatic arthritis or active ankylosing spondylitis.
FDA Alerts
Monday, October 16, 2017
The FDA has approved an expanded indication for ustekinumab (Stelara; Janssen) for the treatment of adolescent patients 12 years or older with moderate to severe plaque psoriasis.

News

News
Thursday, January 18, 2018
Researchers investigated the potential association between cutaneous lymphoma and anti-TNFα therapy in a recent study.
News
Monday, January 8, 2018
Recently, several new biologic agents have been released for the treatment of psoriatic arthritis. Researchers compared the safety and efficacy of these therapies in a recent meta-analysis.
News
Friday, December 22, 2017
Psoriasis is commonly treated by targeting Th17 cells and interleukin 17 cytokines. Although atopic dermatitis is often treated differently, certain subtypes of atopic dermatitis may benefit from certain aspects of psoriasis treatment.
News
Wednesday, December 20, 2017
Although previous studies have shown an association between psoriasis and insulin resistance characteristic for type 2 diabetes, little is currently known about how this condition affects the clinical course of type 1 diabetes.

NPF Endorsed Articles

NPF Endorsed Articles
Tuesday, December 22, 2015
Researchers conducted a systematic literature review of 73 published studies to identify factors associated with treatment non-adherence across diseases in rheumatology, gastroenterology and dermatology.   
NPF Endorsed Articles
Monday, December 21, 2015
In a study published in American Journal of Clinical Dermatology, researchers analyzed the efficacy of adalimumab (Humira, AbbVie Inc.) in patients with psoriasis who previously received systematic therapy. 
NPF Endorsed Articles
Monday, December 21, 2015
​The prevalence of non-alcoholic fatty liver disease (NAFLD) in psoriasis patients was evaluated in a cross-sectional study, recently published in Journal of the European Academy of Dermatology and Venereology. 
NPF Endorsed Articles
Friday, December 18, 2015
Dermira, Inc., a specialty biopharmaceutical company, announced the completion of patient enrollment for the global CIMPASI-1 clinical trial of certolizumab pegol (Cimzia, UCB Inc.) in adult patients with moderate-to-severe chronic plaque psoriasis.

Research in Review

Research in Review
Tuesday, January 9, 2018
The Research Trainee Symposium brings together the sharpest minds in psoriatic disease research.
Research in Review
Tuesday, December 5, 2017
This case evaluates follicular psoriasis, an uncommon variant manifesting as scaly folliculocentric hyperkeratotic eruptions of the trunk and extremities.
Research in Review
Tuesday, December 5, 2017
This 46-year-old woman had been doing well on adalimumab for the treatment of psoriasis for almost 2 years. She presented with what appeared to be a flare of her psoriasis.
Research in Review
Thursday, November 16, 2017
The condition is characterized by an acute, subacute, or chronic eruption of sterile pustules associated with erythema and inflammation. This patient’s case represents the annular variant characterized by pustules on the periphery of expanding erythematous plaques with central healing, most often localized to the trunk.